ArticleScientific reports2021
Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune checkpoint inhibitors-associated acute kidney injury: a systematic review and meta-analysis of incidence, kidney recovery, and recurrent risk.Cancer immunology, immunotherapy : CII · 2025Pooled it
- Guidelines for the prevention and treatment of stress ulcers in critically ill patients (2026).Journal of intensive medicine · 2026Article
- Aspirin Eugenol Ester Alleviates Gastric Injury by Inhibiting Ferroptosis and Oxidative Stress.Antioxidants (Basel, Switzerland) · 2026Article
- Systematic analysis of proton pump inhibitors-related adverse reactions using the FDA adverse event reporting system database.PloS one · 2026Article
- Analysis of infection-related adverse events induced by proton pump inhibitors based on the FAERS and JADER databases.Medicine · 2025Article
- Real-world evaluation of CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer: prognostic effect of proton pump inhibitor use.The oncologist · 2025Article
- Disproportionality Analysis of Renal Adverse Events Associated with a Combination of Immune Checkpoint Inhibitors and Acid-Suppressing Agents-A Pharmacovigilance Study Based on the FAERS Database.Journal of clinical medicine · 2025Article
- Article
- An Integrated Approach for Representing Knowledge on the Potential of Drugs to Cause Acute Kidney Injury.Drug safety · 2025Article
- Accelerated risk of renal disease progression in pre-ESRD patients with proton pump inhibitors use: a nationwide population-based study.BMC nephrology · 2024Article
- Association between preoperative proton pump inhibitor use and postoperative acute kidney injury in patients undergoing major surgery.Renal failure · 2024Article
- A pharmacovigilance study on clinical factors of active vitamin DScientific reports · 2024Article
- Drug-Related Glomerular Phenotypes: A Global Pharmacovigilance Perspective.Journal of clinical medicine · 2024Article
- Acute Kidney Injury Following the Ingestion of a Medicinal Plants' Mixture: A Case Report.Case reports in nephrology · 2024Article
- Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors.Chonnam medical journal · 2023Review
- Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies.Journal of clinical medicine · 2023Article
- Suppression of vacuolar-type ATPase and induction of endoplasmic reticulum stress by proton pump inhibitors.Journal of the Chinese Medical Association : JCMA · 2022Article
- Frequently reported adverse events of rebamipide compared to other drugs for peptic ulcer and gastroesophageal reflux disease.Scientific reports · 2022Article
- Nephroprotective Plants: A Review on the Use in Pre-Renal and Post-Renal Diseases.Plants (Basel, Switzerland) · 2022Review
- Survival and recovery modeling of acute kidney injury in critically ill adults.SAGE open medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton pump inhibitors (PPIs) were widely used. Observational studies suggested increasing risk of kidney injury in patients with PPIs treatment. We gathered six PPI regimens and adverse reports of acute kidney injury (AKI) and chronic kidney disease (CKD) based on US FDA Adverse Event Reporting System (FAERS) database from 2004 to 2019. We employed reporting odds ratio (ROR) to detect signals. Finally, we identified 3187 PPIs-associated AKI cases and 3457 PPIs-associated CKD cases. We detected significant signals between PPIs and AKI as well as CKD. The signal strength was stronger for CKD (ROR = 8.80, 95% CI 8.49-9.13) than AKI (ROR = 3.95, 95% CI 3.81-4.10), while dexlansoprazole performed stronger association for CKD (ROR = 34.94, 95% CI 30.89-39.53) and AKI (ROR = 8.18, 95% CI 7.04-9.51) than the other five PPIs. The median time from PPIs use to event occurrence was 23 days for AKI and 177 days for CKD. PPIs-associated AKI resulted larger proportion of death, life-threatening, hospitalization and disability events than PPIs-associated CKD. By mining the FAERS big data, we provided more information between PPIs use and the AKI and CKD events. PPIs rational use should be repeatedly stressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.